JOHNSON & JOHNSON is 45.3x more valuable than Axsome Therapeutics, Inc. by market capitalization ($574.10 B vs $12.68 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | AXSM | JNJ |
|---|---|---|
| Market cap | $12.68 B | $574.10 B |
| US-listed rank | #813 | #20 |
| Revenue (latest FY) | $638.50M | $94.19B |
| Net income (latest FY) | -$183.17M | $26.80B |
| Net margin | -28.7% | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 634 | 984 |
JOHNSON & JOHNSON is 45.3x more valuable than Axsome Therapeutics, Inc. by market capitalization ($574.10 B vs $12.68 B).
In their latest fiscal years, Axsome Therapeutics, Inc. reported $638.50M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Axsome Therapeutics, Inc. and JOHNSON & JOHNSON, or browse the full rankings.